Breaking News Instant updates and real-time market news.

RETA

Reata Pharmaceuticals

$100.37

4.57 (4.77%)

06:16
10/15/19
10/15
06:16
10/15/19
06:16

Reata shares worth $241 after 'unequivocal upside win,' says Citi

Citi analyst Yigal Nochomovitz raised his price target for Reata Pharmaceuticals to $241 from $194 and reiterates the stock as a top pick with a Buy rating. The stock in premarket trading is up 34%, or $34.43, to $135.02. The registrational Part 2 portion of the MOXIe Phase 2 trial of omaveloxolone in patients with Friedreich's ataxia is a "best case scenario," Nochomovitz tells investors in a research note. The data are an "unequivocal upside win" for Reata, especially amidst very low expectations for the trial, says the analyst. He sees omaveloxolone as a $40-$50 per share opportunity for the company and moved his valuation to a 90% probability of success. This means Reata is now worth $241 per share, says the analyst.

RETA Reata Pharmaceuticals
$100.37

4.57 (4.77%)

09/26/19
SBSH
09/26/19
NO CHANGE
SBSH
Buy
Citi opens 'Positive Catalyst Watch' on Reata Pharmaceuticals
Citi analyst Yigal Nochomovitz opened a 90-day "Positive Catalyst Watch" on Reata Pharmaceuticals ahead of the Phase 3 Cardinal data for bardoxolone in Alport syndrome expected in the second half of 2019. The analyst has a "high conviction" in Alport and expects the stock to be up ~50%-75% on positive data. He also expects investors to assign higher probabilities of success for bardoxolone in other rare nephropathies following the positive Alport data. He keeps a Buy rating on Reata shares.
09/26/19
NATL
09/26/19
INITIATION
Target $130
NATL
Buy
Reata Pharmaceuticals initiated with a Buy at National Securities
National Securities analyst Maria Barbera initiated Reata Pharmaceuticals with a Buy and $130 price target.
10/10/19
STFL
10/10/19
NO CHANGE
Target $135
STFL
Buy
Reata Pharmaceuticals 'bold move' should be well received by Street, says Stifel
Stifel analyst Adam Walsh notes that in "a bold move" likely to be well received by the Street, Reata Pharmaceuticals (RETA) reacquired ex-U.S. rights to BARD, OMAV, and other Nrf2 activators from AbbVie (ABBV) for total deal consideration of $330M. Given AbbVie's lack of a significant renal franchise, the reacquisition of ex-U.S. BARD rights restores strategic flexibility to Reata and provides the opportunity to either find a more engaging development partner, go it alone ex-U.S., or sell the company outright, he contends. Further, the analyst believes the deal terms look "highly reasonable" relative to potential ex-U.S. BARD sales. Walsh has a Buy rating and $135 price target on Reata's shares.
10/14/19
LEER
10/14/19
NO CHANGE
Target $180
LEER
Outperform
Reata Pharmaceuticals price target raised to $180 form $139 at SVB Leerink
SVB Leerink analyst Joseph Schwartz raised his price target for Reata Pharmaceuticals to $180 from $139, while reiterating an Outperform rating on the shares. The analyst believes Bardoxolone methyl remains a key growth driver for Reata with Phase.3 CARDINAL data expected near-term. Additional analysis since his CARDINAL preview suggests that a positive CARDINAL outcome has the potential to lift the stock by 25%-50% and that a valuation of $4B-$7B is reasonable post-data. Lastly, although Phase 3 CARDINAL data are expected after American Society of Nephrology Kidney Week, emerging evidence continues to dispel concerns of hyperfiltration, he contends.

TODAY'S FREE FLY STORIES

NSCO

Nesco Holdings

$4.75

0.04 (0.85%)

20:44
11/11/19
11/11
20:44
11/11/19
20:44
Earnings
Nesco Holdings cuts FY19 revenue view to $255M-$262M from $278M »

One estimate $279.6M. …

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

NSCO

Nesco Holdings

$4.75

0.04 (0.85%)

20:42
11/11/19
11/11
20:42
11/11/19
20:42
Earnings
Nesco Holdings reports Q3 EPS (45c), one estimate 4c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

FTK

Flotek

$1.86

-0.1 (-5.10%)

20:29
11/11/19
11/11
20:29
11/11/19
20:29
Earnings
Flotek reports Q3 EPS (19c), one estimate (23c) »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

RF

Regions Financial

$16.77

-0.1 (-0.59%)

20:27
11/11/19
11/11
20:27
11/11/19
20:27
Downgrade
Regions Financial rating change at BMO Capital »

Regions Financial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

TSN

Tyson Foods

$82.70

0.12 (0.15%)

, ROK

Rockwell Automation

$180.00

2.25 (1.27%)

20:25
11/11/19
11/11
20:25
11/11/19
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

TSN

Tyson Foods

$82.70

0.12 (0.15%)

ROK

Rockwell Automation

$180.00

2.25 (1.27%)

DHI

D.R. Horton

$52.65

1.535 (3.00%)

CBS

CBS

$39.21

1.09 (2.86%)

AAP

Advance Auto Parts

$168.41

1.17 (0.70%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

  • 12

    Nov

  • 12

    Nov

  • 12

    Nov

  • 12

    Nov

  • 18

    Nov

  • 19

    Nov

  • 20

    Nov

  • 09

    Dec

RMTI

Rockwell Medical

$1.92

0.07 (3.78%)

20:01
11/11/19
11/11
20:01
11/11/19
20:01
Recommendations
Rockwell Medical analyst commentary at Piper Jaffray »

Rockwell Medical price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Nov

APYX

Apyx Medical

$7.22

0.24 (3.44%)

19:39
11/11/19
11/11
19:39
11/11/19
19:39
Recommendations
Apyx Medical analyst commentary at Piper Jaffray »

Apyx Medical price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Nov

  • 12

    Nov

FOE

Ferro

$12.58

0.07 (0.56%)

, APYX

Apyx Medical

$7.22

0.24 (3.44%)

18:59
11/11/19
11/11
18:59
11/11/19
18:59
Hot Stocks
Fly Intel: After Hours Movers »

UP AFTER EARNINGS: Ferro…

FOE

Ferro

$12.58

0.07 (0.56%)

APYX

Apyx Medical

$7.22

0.24 (3.44%)

KEM

Kemet

$23.03

-0.51 (-2.17%)

ICUI

ICU Medical

$168.41

1.43 (0.86%)

LONE

Lonestar Resources

$2.88

0.08 (2.86%)

GO

Grocery Outlet

$31.09

-0.06 (-0.19%)

CMLS

Cumulus Media

$13.59

0.07 (0.52%)

FGEN

FibroGen

$35.37

-6.24 (-15.00%)

DXC

DXC Technology

$29.39

-0.69 (-2.29%)

BREW

Craft Brew

$7.33

0.06 (0.83%)

LYV

Live Nation

$64.47

1.31 (2.07%)

FLNT

Fluent

$2.54

0.11 (4.53%)

ASUR

Asure Software

$9.20

0.01 (0.11%)

UGI

UGI Corporation

$46.21

-0.35 (-0.75%)

HBM

Hudbay Minerals

$3.66

-0.09 (-2.40%)

FPI

Farmland Partners

$6.66

-0.125 (-1.84%)

RETA

Reata Pharmaceuticals

$213.52

1.48 (0.70%)

JCOM

j2 Global

$100.62

0.23 (0.23%)

PCG

PG&E

$6.24

-0.23 (-3.55%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Nov

  • 11

    Nov

  • 11

    Nov

  • 11

    Nov

  • 11

    Nov

  • 11

    Nov

  • 11

    Nov

  • 11

    Nov

  • 11

    Nov

  • 12

    Nov

  • 12

    Nov

  • 12

    Nov

  • 12

    Nov

  • 12

    Nov

  • 12

    Nov

  • 12

    Nov

  • 12

    Nov

  • 12

    Nov

  • 12

    Nov

  • 13

    Nov

  • 19

    Nov

  • 09

    Dec

  • 07

    Jan

CRL

Charles River

$131.58

1.19 (0.91%)

18:57
11/11/19
11/11
18:57
11/11/19
18:57
Hot Stocks
Charles River CEO: We are pleased with the demand curve »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PCG

PG&E

$6.24

-0.23 (-3.55%)

18:44
11/11/19
11/11
18:44
11/11/19
18:44
Periodicals
PG&E offers $13.5B in compensation to victims of CA fires, Bloomberg says »

PG&E is offering to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

  • 07

    Jan

KEM

Kemet

$23.03

-0.51 (-2.17%)

18:27
11/11/19
11/11
18:27
11/11/19
18:27
Hot Stocks
Breaking Hot Stocks news story on Kemet »

Kemet up 14.7% to $26.40…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

NCLH

Norwegian Cruise Line

$51.90

0.07 (0.14%)

18:23
11/11/19
11/11
18:23
11/11/19
18:23
Hot Stocks
Norwegian Cruise Line CEO: North American consumer is alive and well »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FOE

Ferro

$12.58

0.07 (0.56%)

18:23
11/11/19
11/11
18:23
11/11/19
18:23
Earnings
Ferro reports Q3 adjusted EPS 35c, consensus 28c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

  • 12

    Nov

KEM

Kemet

$23.03

-0.51 (-2.17%)

18:09
11/11/19
11/11
18:09
11/11/19
18:09
Hot Stocks
Yageo to acquire Kemet for $27.20 per share in cash, or $1.8B »

Yageo and Kemet announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

PAR

Par Technology

$30.23

1.07 (3.67%)

18:08
11/11/19
11/11
18:08
11/11/19
18:08
Recommendations
Par Technology analyst commentary at Jefferies »

Par Technology price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KEM

Kemet

$23.03

-0.51 (-2.17%)

18:06
11/11/19
11/11
18:06
11/11/19
18:06
Hot Stocks
Breaking Hot Stocks news story on Kemet »

Yageo to acquire Kemet…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

CSX

CSX

$73.93

-0.08 (-0.11%)

18:03
11/11/19
11/11
18:03
11/11/19
18:03
Downgrade
CSX rating change at Deutsche Bank »

CSX downgraded to Hold…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

TDW

Tidewater

$17.14

-0.34 (-1.95%)

18:03
11/11/19
11/11
18:03
11/11/19
18:03
Earnings
Tidewater reports Q3 adjusted EPS (99c), may not compare to consensus (10c) »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

UNVR

Univar

$23.87

-0.08 (-0.33%)

17:57
11/11/19
11/11
17:57
11/11/19
17:57
Hot Stocks
Univar named EMEA distributor for Kaopolite Abrasive in Europe »

Univar B.V., a subsidiary…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NXRT

NexPoint Residential

$46.48

0.44 (0.96%)

17:56
11/11/19
11/11
17:56
11/11/19
17:56
Hot Stocks
NexPoint Residential acquires three-property portfolio in Las Vegas for $241M »

NexPoint Residential…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

DXC

DXC Technology

$29.39

-0.69 (-2.29%)

17:40
11/11/19
11/11
17:40
11/11/19
17:40
Hot Stocks
Breaking Hot Stocks news story on DXC Technology »

DXC reverses course, now…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Nov

FLNT

Fluent

$2.54

0.11 (4.53%)

17:40
11/11/19
11/11
17:40
11/11/19
17:40
Hot Stocks
Fluent drops over 22% after reporting Q3 results, lowers FY19 revenue view »

Shares of Fluent are down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Nov

LYV

Live Nation

$64.47

1.31 (2.07%)

17:38
11/11/19
11/11
17:38
11/11/19
17:38
Upgrade
Live Nation rating change  »

Live Nation upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DXC

DXC Technology

$29.39

-0.69 (-2.29%)

17:38
11/11/19
11/11
17:38
11/11/19
17:38
Hot Stocks
DXC Technology to pursue strategic alternatives for three businesses »

Says as part of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Nov

FLNT

Fluent

$2.54

0.11 (4.53%)

17:38
11/11/19
11/11
17:38
11/11/19
17:38
Earnings
Fluent lowers FY19 revenue view to $87M-$88M from $93M-$98M »

Sees adjusted EBITDA is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.